Skip to main content

    WestPark Capital starts coverage of Akebia Ther (AKBA) at Buy

    GNG Research Market News

    By GNG Research

    WestPark Capital initiated coverage of Akebia Ther (AKBA) at Buy on September 8, 2026.

    Among three firms active over the past 90 days, three hold a bullish rating. As of October 30, 2026, seven analysts place the consensus mean at $3.57, the median at $4.08 and the range at $1.01 to $4.73.

    The Q4 FY2026 consensus calls for -$0.04 in EPS on $49.15 million in revenue. The next earnings date is February 24, 2027.